Recently, Qianjin Pharmaceutical announced that it has successfully obtained the drug registration certificate for Hydrotalcite Tablets from China’s National Medical Products Administration (NMPA). This approval marks a significant step forward in the company’s expansion into the gastrointestinal therapeutic area and further diversifies its product portfolio. Hydrotalcite is a commonly used antacid widely prescribed for conditions such as excessive gastric acid, gastritis, gastric ulcers, and duodenal ulcers. It works by neutralizing stomach acid and protecting the gastric mucosa, offering rapid onset of action and minimal side effects, which has led to its widespread clinical use and proven efficacy. The registration certificate not only demonstrates Qianjin Pharmaceutical’s strong capabilities in drug development and quality control but also lays a solid foundation for its future growth in the gastrointestinal disease treatment market. With the rising prevalence of digestive disorders in China, hydrotalcite—being a first-line therapy—holds considerable market potential. Qianjin Pharmaceutical stated that it will accelerate the product’s commercialization process to bring it to market as soon as possible, meeting patient needs and creating a new driver for revenue growth.
近日，千金药业宣布成功获得国家药品监督管理局颁发的铝碳酸镁片药品注册证书。这一获批标志着公司在消化系统用药领域迈出了重要一步，进一步丰富了其产品管线。铝碳酸镁是一种常用的抗酸药，广泛用于治疗胃酸过多、胃炎、胃溃疡及十二指肠溃疡等消化道疾病。该药物通过中和胃酸、保护胃黏膜，具有起效快、副作用小的特点，临床应用广泛且疗效确切。千金药业此次获得注册证书，不仅体现了其在药品研发与质量控制方面的实力，也为公司未来在胃肠疾病治疗市场的拓展奠定了坚实基础。随着国内消化系统疾病患者数量持续增长，铝碳酸镁作为一线治疗药物，市场前景广阔。千金药业表示，将加快该产品的产业化进程，尽快实现上市销售，以满足广大患者的用药需求，并为公司带来新的业绩增长点。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22210.html